Swine, Ruminant and Companion Animals Vaccines Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis (2017-2021) and Forecast (2022-2028)

$ PRICE - $ 3,000.00$ 8,900.00

Swine, Ruminant and Companion Animals Vaccines Market: By Product (Swine Vaccine, Cattle Vaccine, Companion Animal Vaccines), by By Disease (Swine Disease, Cattle Diseases, Companion Animal Diseases) and Geography

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Category:

Report

Description

The swine, ruminant and companion animal vaccines market is USD 4,656.6 million in 2021, with a strong CAGR of 6.1 percent expected from 2022 to 2028. The swine, ruminant, and companion animal vaccines market is expected to experience steady growth due to increased pet ownership in developed countries and a rise in the number of cattle & poultry in developing countries. Furthermore, the rise in investment in research and development of vaccines, which inhibit the growth of antibiotic-resistant organisms, boosts the growth of the swine, ruminant, and companion animal vaccines market. Productivity in livestock is severely impacted by the presence of a few bacterial, viral, and protozoan borne diseases. Timely vaccination prevents the risk of infection and affects a farmer’s income through livestock rearing. Furthermore, the rate of developing infectious diseases continues to rise, necessitating the rapid deployment of new vaccinations. For effective disease eradication, it is critical to identify such diseases and vaccinate animals regularly. Because of advancements in technology and medicine and our comprehensive knowledge of immunology, molecular biology, microbiology, and biochemistry, among other basic science fields, new vaccine manufacturing methods have emerged, providing several chances to key market players. In the swine, ruminant, and companion animal vaccines market size, the attenuated vaccines segment dominated the product type segment with the largest share. By stimulating a wide spectrum of immune responses, attenuated vaccines can deliver better immunity than conventional vaccines. Furthermore, it helps to lessen the need for booster vaccinations that can be given orally and generates long-lasting and fast immunity, all of which contribute to the growth of the swine, ruminant, and companion animal vaccines market.

Recent Market Developments:

In August 2021, Zoetis Inc. announced it has entered into an agreement to acquire Jurox, a privately held animal health company, which develops, manufactures, and markets a wide range of veterinary medicines for treating companion animals and livestock. Jurox’s operations are based in Australia, with additional regional offices and subsidiaries in New Zealand, U.S., Canada, and the UK. Financial terms of the transaction are not being disclosed.

In August 2021, as part of Sanofi’s endeavor to accelerate the application of messenger RNA (mRNA) to develop therapeutics and vaccines, the company has entered into a definitive agreement with Translate Bio a clinical-stage mRNA therapeutics company, under which Sanofi will acquire all outstanding shares of Translate Bio for $38.00 per share in cash, which represents a total equity value of approximately $3.2 billion

Swine, Ruminant and Companion Animals Vaccines Market

MARKET SUMMARY
-
6.1% CAGR
  • Study Period– 2022-2028
  • Base Year– 2021
  • CAGR– 6.1%
  • Largest Market– North America
  • Fastest Growing Market– Europe

Swine Ruminant and

Companion Animals Vaccines Market

  • The swine, ruminant and companion animals vaccines market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • The swine, ruminant and companion animals vaccines market report gives historical, current, and future market sizes (US$ Mn) based on by product, disease and geography.
Key Players
  • Ceva Sante Animale
  • Elanco
  • Merial
  • Vetoquinol
  • Zoetis Inc.
Swine, Ruminant and Companion Animals Vaccines Market Drivers

The rising prevalence of zoonotic illnesses could negatively influence human health, driving up demand for swine, ruminant, and companion animal vaccines. Human and animal health are increasingly threatened by emerging and exotic animal illnesses, undermining food security. Furthermore, the lack of animal health awareness and the potential for adverse effects of veterinary vaccinations on human and other animal health limit the market’s growth.


North-America Got Significant Share

Swine, Ruminant and Companion Animals Vaccines Market

In 2021, North America led the market and held a bigger share. The high incidence of livestock and zoonotic illnesses, which result in large-scale animal mortality, can be blamed for this enormous share. Furthermore, due to the large number of well-established pharmaceutical companies that are continually attempting to expand their geographical reach and commercialize their vaccines, the market is expected to grow. In addition, the increased prevalence of canine illnesses, which is driving up vaccination adoption, and the growing pet population in the United States are two significant factors driving the regional market forward.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The swine, ruminant and companion animals vaccines market report provides granular level information about the market size, regional market share, historic market (2017-2021) and forecast (2022-2028)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Swine, Ruminant and Companion Animals Vaccines Market

Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

The Swine, Ruminant and Companion Animals Vaccines Market is projected to expand at a CAGR of 6.1% during the forecast period.

The major players in the global swine, ruminant, and companion animals vaccines market are ​​​ Boehringer Ingelheim International GmbH., IDT Biologika GmbH, HIPRA, Ceva Sante Animale, Elanco, Arko Laboratories Ltd, Merial, Vetoquinol, Zoetis Inc., Phibro Animal Health Corporation, Merck & Co., Inc., and Virbac.

Europe is the fastest-growing region for Swine, Ruminant and Companion Animals Vaccines Market


Report

Table Of Content

1. Executive Summary
2. Global Swine, Ruminant and Companion Animals Vaccines Market Introduction
2.1. Global Swine, Ruminant and Companion Animals Vaccines Market – Taxonomy
2.2. Global Swine, Ruminant and Companion Animals Vaccines Market –Definitions
2.2.1. By Product
2.2.2. By Disease
2.2.3. By Region
3. Global Swine, Ruminant and Companion Animals Vaccines Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Swine, Ruminant and Companion Animals Vaccines Market Dynamic Factors – Impact Analysis
4. Global Swine, Ruminant and Companion Animals Vaccines Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028
4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Swine, Ruminant and Companion Animals Vaccines Market, By Product, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1. Swine Vaccine
5.1.1. Inactivated Vaccines
5.1.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.1.3. Market Opportunity Analysis
5.1.2. Live Attenuated Vaccines
5.1.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.2.3. Market Opportunity Analysis
5.1.3. Others
5.1.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3.3. Market Opportunity Analysis
5.2. Cattle Vaccine
5.2.1. Toxoid
5.2.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.1.3. Market Opportunity Analysis
5.2.2. Recombinant
5.2.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.2.3. Market Opportunity Analysis
5.2.3. Inactivated
5.2.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3.3. Market Opportunity Analysis
5.3. Companion Animal Vaccines
5.3.1. Attenuated Live Vaccine
5.3.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.3.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.1.3. Market Opportunity Analysis
5.3.2. Inactivated Vaccine
5.3.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.3.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.2.3. Market Opportunity Analysis
5.3.3. Others
5.3.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.3.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3.3. Market Opportunity Analysis
6. Global Swine, Ruminant and Companion Animals Vaccines Market, By Disease, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.1. Swine Disease
6.1.1. Diarrhea
6.1.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.1.3. Market Opportunity Analysis
6.1.2. Swine Influenza
6.1.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.2.3. Market Opportunity Analysis
6.1.3. Bordetella Rhinitis
6.1.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3.3. Market Opportunity Analysis
6.1.4. Porcine Reproductive and Respiratory Syndrome (PRRS)
6.1.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.4.3. Market Opportunity Analysis
6.1.5. Porcine Circovirus Associated Disease (PCVAD)
6.1.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.1.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.5.3. Market Opportunity Analysis
6.1.6. Other Diseases
6.1.6.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.1.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.6.3. Market Opportunity Analysis
6.2. Cattle Diseases
6.2.1. FMD
6.2.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.1.3. Market Opportunity Analysis
6.2.2. Infectious Respiratory Diseases
6.2.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.2.3. Market Opportunity Analysis
6.2.3. Reproductive Disorders
6.2.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3.3. Market Opportunity Analysis
6.2.4. Others
6.2.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.2.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.4.3. Market Opportunity Analysis
6.3. Companion Animal Diseases
6.3.1. Rabies
6.3.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.3.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.1.3. Market Opportunity Analysis
6.3.2. Hepatitis
6.3.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.3.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.2.3. Market Opportunity Analysis
6.3.3. Leukemia
6.3.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.3.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3.3. Market Opportunity Analysis
6.3.4. Others
6.3.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.3.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.4.3. Market Opportunity Analysis
7. Global Swine, Ruminant and Companion Animals Vaccines Market Forecast, By Region, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.1. North America
7.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Europe
7.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Asia-Pacific
7.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Latin America
7.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Middle East and Africa
7.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
7.6. Global Swine, Ruminant and Companion Animals Vaccines Market – Opportunity Analysis Index, By Product, Disease, and Region, 2022 – 2028
8. North America Swine, Ruminant and Companion Animals Vaccines Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.1. Product Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
8.1.1. Swine Vaccine
8.1.1.1. Inactivated Vaccines
8.1.1.2. Live Attenuated Vaccines
8.1.1.3. Others
8.1.2. Cattle Vaccine
8.1.2.1. Toxoid
8.1.2.2. Recombinant
8.1.2.3. Inactivated
8.1.3. Companion Animal Vaccines
8.1.3.1. Attenuated Live Vaccine
8.1.3.2. Inactivated Vaccine
8.1.3.3. Others
8.2. Disease Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
8.2.1. Swine Diseases
8.2.1.1. Diarrhea
8.2.1.2. Swine Influenza
8.2.1.3. Bordetella Rhinitis
8.2.1.4. Porcine Reproductive and Respiratory Syndrome (PRRS)
8.2.1.5. Porcine Circovirus Associated Disease (PCVAD)
8.2.1.6. Other Diseases
8.2.2. Cattle Diseases
8.2.2.1. FMD
8.2.2.2. Infectious Respiratory Diseases
8.2.2.3. Reproductive Disorders
8.2.2.4. Others
8.2.3. Companion Animal Diseases
8.2.3.1. Rabies
8.2.3.2. Hepatitis
8.2.3.3. Leukemia
8.2.3.4. Others
8.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
8.3.1. USA
8.3.2. Canada
8.4. North America Swine, Ruminant and Companion Animals Vaccines Market – Opportunity Analysis Index, By Product, Disease, and Country, 2022 – 2028
8.5. North America Swine, Ruminant and Companion Animals Vaccines Market Dynamics – Trends
9. Europe Swine, Ruminant and Companion Animals Vaccines Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
9.1. Product Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Swine Vaccine
9.1.1.1. Inactivated Vaccines
9.1.1.2. Live Attenuated Vaccines
9.1.1.3. Others
9.1.2. Cattle Vaccine
9.1.2.1. Toxoid
9.1.2.2. Recombinant
9.1.2.3. Inactivated
9.1.3. Companion Animal Vaccines
9.1.3.1. Attenuated Live Vaccine
9.1.3.2. Inactivated Vaccine
9.1.3.3. Others
9.2. Disease Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.2.1. Swine Diseases
9.2.1.1. Diarrhea
9.2.1.2. Swine Influenza
9.2.1.3. Bordetella Rhinitis
9.2.1.4. Porcine Reproductive and Respiratory Syndrome (PRRS)
9.2.1.5. Porcine Circovirus Associated Disease (PCVAD)
9.2.1.6. Other Diseases
9.2.2. Cattle Diseases
9.2.2.1. FMD
9.2.2.2. Infectious Respiratory Diseases
9.2.2.3. Reproductive Disorders
9.2.2.4. Others
9.2.3. Companion Animal Diseases
9.2.3.1. Rabies
9.2.3.2. Hepatitis
9.2.3.3. Leukemia
9.2.3.4. Others
9.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.3.1. Germany
9.3.2. UK
9.3.3. France
9.3.4. Spain
9.3.5. Italy
9.3.6. Russia
9.3.7. Rest of Europe
9.4. Europe Swine, Ruminant and Companion Animals Vaccines Market – Opportunity Analysis Index, By Product, Disease, and Country, 2022 – 2028
9.5. Europe Swine, Ruminant and Companion Animals Vaccines Market Dynamics – Trends
10. Asia-Pacific Swine, Ruminant and Companion Animals Vaccines Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
10.1. Product Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Swine Vaccine
10.1.1.1. Inactivated Vaccines
10.1.1.2. Live Attenuated Vaccines
10.1.1.3. Others
10.1.2. Cattle Vaccine
10.1.2.1. Toxoid
10.1.2.2. Recombinant
10.1.2.3. Inactivated
10.1.3. Companion Animal Vaccines
10.1.3.1. Attenuated Live Vaccine
10.1.3.2. Inactivated Vaccine
10.1.3.3. Others
10.2. Disease Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Swine Diseases
10.2.1.1. Diarrhea
10.2.1.2. Swine Influenza
10.2.1.3. Bordetella Rhinitis
10.2.1.4. Porcine Reproductive and Respiratory Syndrome (PRRS)
10.2.1.5. Porcine Circovirus Associated Disease (PCVAD)
10.2.1.6. Other Diseases
10.2.2. Cattle Diseases
10.2.2.1. FMD
10.2.2.2. Infectious Respiratory Diseases
10.2.2.3. Reproductive Disorders
10.2.2.4. Others
10.2.3. Companion Animal Diseases
10.2.3.1. Rabies
10.2.3.2. Hepatitis
10.2.3.3. Leukemia
10.2.3.4. Others
10.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.3.1. China
10.3.2. India
10.3.3. Japan
10.3.4. ASEAN
10.3.5. Australia & New Zealand
10.3.6. Rest of Asia-Pacific
10.4. Asia-Pacific Swine, Ruminant and Companion Animals Vaccines Market – Opportunity Analysis Index, By Product, Disease, and Country, 2022 – 2028
10.5. Asia-Pacific Swine, Ruminant and Companion Animals Vaccines Market Dynamics – Trends
11. Latin America Swine, Ruminant and Companion Animals Vaccines Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
11.1. Product Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Swine Vaccine
11.1.1.1. Inactivated Vaccines
11.1.1.2. Live Attenuated Vaccines
11.1.1.3. Others
11.1.2. Cattle Vaccine
11.1.2.1. Toxoid
11.1.2.2. Recombinant
11.1.2.3. Inactivated
11.1.3. Companion Animal Vaccines
11.1.3.1. Attenuated Live Vaccine
11.1.3.2. Inactivated Vaccine
11.1.3.3. Others
11.2. Disease Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.2.1. Swine Diseases
11.2.1.1. Diarrhea
11.2.1.2. Swine Influenza
11.2.1.3. Bordetella Rhinitis
11.2.1.4. Porcine Reproductive and Respiratory Syndrome (PRRS)
11.2.1.5. Porcine Circovirus Associated Disease (PCVAD)
11.2.1.6. Other Diseases
11.2.2. Cattle Diseases
11.2.2.1. FMD
11.2.2.2. Infectious Respiratory Diseases
11.2.2.3. Reproductive Disorders
11.2.2.4. Others
11.2.3. Companion Animal Diseases
11.2.3.1. Rabies
11.2.3.2. Hepatitis
11.2.3.3. Leukemia
11.2.3.4. Others
11.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.3.1. Brazil
11.3.2. Mexico
11.3.3. Rest of Latin America
11.4. Latin America Swine, Ruminant and Companion Animals Vaccines Market – Opportunity Analysis Index, By Product, Disease, and Country, 2022 – 2028
11.5. Latin America Swine, Ruminant and Companion Animals Vaccines Market Dynamics – Trends
12. Middle East and Africa Swine, Ruminant and Companion Animals Vaccines Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
12.1. Product Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Swine Vaccine
12.1.1.1. Inactivated Vaccines
12.1.1.2. Live Attenuated Vaccines
12.1.1.3. Others
12.1.2. Cattle Vaccine
12.1.2.1. Toxoid
12.1.2.2. Recombinant
12.1.2.3. Inactivated
12.1.3. Companion Animal Vaccines
12.1.3.1. Attenuated Live Vaccine
12.1.3.2. Inactivated Vaccine
12.1.3.3. Others
12.2. Disease Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.2.1. Swine Diseases
12.2.1.1. Diarrhea
12.2.1.2. Swine Influenza
12.2.1.3. Bordetella Rhinitis
12.2.1.4. Porcine Reproductive and Respiratory Syndrome (PRRS)
12.2.1.5. Porcine Circovirus Associated Disease (PCVAD)
12.2.1.6. Other Diseases
12.2.2. Cattle Diseases
12.2.2.1. FMD
12.2.2.2. Infectious Respiratory Diseases
12.2.2.3. Reproductive Disorders
12.2.2.4. Others
12.2.3. Companion Animal Diseases
12.2.3.1. Rabies
12.2.3.2. Hepatitis
12.2.3.3. Leukemia
12.2.3.4. Others
12.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.3.1. Gulf Cooperation Council (GCC) Countries
12.3.2. South Africa
12.3.3. Rest of MEA
12.4. MEA Swine, Ruminant and Companion Animals Vaccines Market – Opportunity Analysis Index, By Product, Disease, and Country, 2022 – 2028
12.5. MEA Swine, Ruminant and Companion Animals Vaccines Market Dynamics – Trends
13. Competition Landscape 
13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, Product Offerings, Key Developments, Strategies, and SWOT Analysis)
13.2.1. Boehringer Ingelheim International GmbH.
13.2.2. IDT Biologika GmbH
13.2.3. HIPRA
13.2.4. Ceva Sante Animale
13.2.5. Elanco
13.2.6. Arko Laboratories Ltd
13.2.7. Merial
13.2.8. Vetoquinol
13.2.9. Zoetis Inc.
13.2.10. Phibro Animal Health Corporation
13.2.11. Merck & Co., Inc.
13.2.12. Virbac
14. Research Methodology
15. Key Assumptions and Acronyms

Report

Company Profile

  • Boehringer Ingelheim International GmbH.
  • IDT Biologika GmbH
  • HIPRA
  • Ceva Sante Animale
  • Elanco
  • Arko Laboratories Ltd
  • Merial
  • Vetoquinol
  • Zoetis Inc.
  • Phibro Animal Health Corporation
  • Merck & Co., Inc.
  • Virbac

Description

The swine, ruminant and companion animal vaccines market is USD 4,656.6 million in 2021, with a strong CAGR of 6.1 percent expected from 2022 to 2028. The swine, ruminant, and companion animal vaccines market is expected to experience steady growth due to increased pet ownership in developed countries and a rise in the number of cattle & poultry in developing countries. Furthermore, the rise in investment in research and development of vaccines, which inhibit the growth of antibiotic-resistant organisms, boosts the growth of the swine, ruminant, and companion animal vaccines market. Productivity in livestock is severely impacted by the presence of a few bacterial, viral, and protozoan borne diseases. Timely vaccination prevents the risk of infection and affects a farmer’s income through livestock rearing. Furthermore, the rate of developing infectious diseases continues to rise, necessitating the rapid deployment of new vaccinations. For effective disease eradication, it is critical to identify such diseases and vaccinate animals regularly. Because of advancements in technology and medicine and our comprehensive knowledge of immunology, molecular biology, microbiology, and biochemistry, among other basic science fields, new vaccine manufacturing methods have emerged, providing several chances to key market players. In the swine, ruminant, and companion animal vaccines market size, the attenuated vaccines segment dominated the product type segment with the largest share. By stimulating a wide spectrum of immune responses, attenuated vaccines can deliver better immunity than conventional vaccines. Furthermore, it helps to lessen the need for booster vaccinations that can be given orally and generates long-lasting and fast immunity, all of which contribute to the growth of the swine, ruminant, and companion animal vaccines market.

Recent Market Developments:

In August 2021, Zoetis Inc. announced it has entered into an agreement to acquire Jurox, a privately held animal health company, which develops, manufactures, and markets a wide range of veterinary medicines for treating companion animals and livestock. Jurox’s operations are based in Australia, with additional regional offices and subsidiaries in New Zealand, U.S., Canada, and the UK. Financial terms of the transaction are not being disclosed.

In August 2021, as part of Sanofi’s endeavor to accelerate the application of messenger RNA (mRNA) to develop therapeutics and vaccines, the company has entered into a definitive agreement with Translate Bio a clinical-stage mRNA therapeutics company, under which Sanofi will acquire all outstanding shares of Translate Bio for $38.00 per share in cash, which represents a total equity value of approximately $3.2 billion

Reviews

There are no reviews yet.

Be the first to review “Swine, Ruminant and Companion Animals Vaccines Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis (2017-2021) and Forecast (2022-2028)”

Your email address will not be published. Required fields are marked *

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX